Stay Up to Date
with SHINE

SHINE and Standard Nuclear announce partnership plan to turn nuclear waste into fuel for advanced reactors—creating a circular economy that makes nuclear energy renewable while strengthening America's energy security.

SHINE is proving fusion can help the world today—long before it powers the grid. This Washington Post article explores how our approach differs from the race for electricity.

SHINE celebrates Ilumira's first anniversary with strong commercial growth, global expansion to 19 countries, and strategic moves including EMA submission and SPECT acquisition positioning for nuclear medicine leadership.

SHINE adds healthcare innovator Dr. Gregory Sorensen to its Board and defense expert Col. (Ret.) Gregory Van Dyk as Strategic Advisor to expand fusion applications across commercial and defense sectors.

SHINE is acquiring Lantheus’ SPECT business to expand access to life-saving isotopes, accelerate innovation, and strengthen its position in the growing nuclear medicine market.

SHINE partners with Modawina Medical Company to distribute Ilumira in the UAE, expanding global access to cancer-fighting isotopes and strengthening SHINE's presence in the EMEA region.

Strategic alliance set to strengthen supply chains for medical isotopes, industrial applications, and fusion technologies between North America and Asia.

Canary Media explores how our path to fusion energy begins with profitable medical and industrial applications.

Wisconsin Technology Council explores how we're making fusion technology commercially viable today while building toward tomorrow's clean energy future.

Funding Part of Advanced Research Projects Agency-Energy (ARPA-E) Program to Enable Transmutation of U.S. Commercial Nuclear Stockpile

SHINE's DT fusion system to power breakthrough tritium breeding research at UKAEA's LIBRTI program to advance fusion energy development

Antelope Surgical Solutions, Inc. and SHINE Technologies announced a supply agreement to accelerate Antelope’s clinical development of its targeted radiopharmaceutical candidates.

Primo Biotech partners with SHINE Technologies for exclusive distribution of Ilumira™ (n.c.a. lutetium-177) in Taiwan, with additional rights in Japan, South Korea & Singapore. Aims to expand nuclear medicine access in Asia.

Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies

Newsweek featured us in their latest issue. The story describes how we're using fusion tech today while building toward a cleaner energy future.